News
Compounded GLP-1 Regulatory News
Latest — updated August 10, 2026
Where the rulebook stands:
503B exclusion comment window closes; no final rule yet
The FDA's April 30 proposal to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list reached the end of its extended comment period in early August. Finalization would foreclose bulk compounding even in a future shortage; patient-specific 503A prescribing is unaffected.
Monitored category — items publish only when newsworthy and sourced.
The regulation category tracks FDA, FTC, state pharmacy board, and court developments affecting compounded GLP-1 access. Each item names the agency, the action, the date, and the affected products, and links the official notice rather than secondary coverage.
What we watch in this category
- FDA compounding guidance and enforcement
- FTC actions on marketing claims
- State board rules on nonresident compounding
- Litigation affecting compounded GLP-1 availability
Primary sources monitored
Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.